Proposed Section Structure
For this topic, a clinically useful structure should move from the biomarker problem in everyday practice to the multicohort evidence, then to mechanistic interpretation and implementation. The most appropriate organization is: Highlights; Clinical Context and Unmet Need; Study Design and Cohorts; Main Results; Experimental Mechanistic Findings; Clinical Interpretation and Implications for Acute Care; Strengths and Limitations; Conclusion; Funding and Trial Information; References. This sequence mirrors how clinicians assess a potentially practice-changing biomarker study: first asking whether the signal is real, then whether it is biologically plausible, and finally whether it is actionable.
Highlights
First, this study directly challenges the long-standing practical assumption that cardiac troponin I and cardiac troponin T can be treated as interchangeable indicators of myocardial injury.
Second, across 9,704 adjudicated participants from prospective cohorts, the cTnI/cTnT ratio was substantially higher in acute cardiac disease than in chronic cardiac disease or in those without known cardiac disease.
Third, the directional clinical signal was reproduced across alternative high-sensitivity cTnI assays, external validation cohorts, and experimental cardiomyocyte models, strengthening biological credibility.
Fourth, adding the cTnI/cTnT ratio to models containing both biomarkers modestly but significantly improved discrimination between type 1 and type 2 acute myocardial infarction.
Background and Clinical Context
Cardiac troponins are foundational biomarkers in contemporary cardiovascular medicine. High-sensitivity cardiac troponin assays are now central to diagnosing acute myocardial infarction, risk stratification in emergency care, and prognostication across a wide range of cardiovascular and systemic illnesses. Yet clinical practice often treats hs-cTnI and hs-cTnT as broadly interchangeable markers of cardiomyocyte injury, especially once assay-specific thresholds are accounted for.
That convention has always been practical rather than strictly biological. Troponin I and troponin T are distinct proteins within the cardiac contractile apparatus, measured by different commercial assays with different analytical characteristics, kinetics, and susceptibility to nonischemic elevation. Prior observational work has suggested that cTnT may be disproportionately elevated in chronic structural heart disease, renal dysfunction, and subclinical myocardial stress, whereas cTnI may track more closely with acute necrotic injury in some settings. However, these observations have usually come from smaller studies, mixed populations, or single-assay analyses.
The clinical problem is clear. Elevated troponin is common, but the meaning of that elevation varies considerably. Emergency physicians, internists, and cardiologists must often decide whether a patient has acute plaque rupture with cardiomyocyte necrosis, supply-demand mismatch, chronic myocardial injury, or a nonischemic injury pattern. A biomarker construct that helps distinguish acute necrotic from chronic or non-necrotic myocardial injury would therefore be valuable, particularly when the absolute troponin value alone is ambiguous.
Study Design
Clinical cohorts and population
Zimmermann and colleagues assembled participants from three prospective clinical studies with centrally adjudicated diagnoses, yielding a large total population of 9,704 individuals. Participants were categorized into three clinically meaningful groups: no known cardiac disease, chronic cardiac disease, and acute cardiac disease. This adjudicated multicohort design is a major strength because it reduces diagnostic noise and permits comparison of the ratio across clinically distinct states of myocardial injury.
Biomarker measurement and analytic framework
The investigators measured hs-cTnI with the Architect platform and hs-cTnT with the Elecsys platform. Regression models were used to test the relationship between the cTnI/cTnT ratio and diagnostic category, and to assess the incremental diagnostic utility of the ratio. The study further performed internal and external validation, including analyses with alternative hs-cTnI assays. This is particularly important because any biomarker ratio can be distorted by platform-specific calibration, imprecision, or epitope targeting.
Experimental component
To address biological plausibility, the investigators complemented the clinical analysis with four experimental cardiomyocyte models simulating mild nonlethal injury and lethal injury. This translational design is one of the most compelling aspects of the paper because it tests whether the observed clinical signal reflects genuine differences in release biology rather than only assay artifact or population confounding.
Endpoints of interest
The central endpoint was whether the cTnI/cTnT ratio differed meaningfully across injury phenotypes, especially acute versus chronic or non-necrotic myocardial injury. An additional clinically relevant endpoint was whether the ratio improved discrimination between type 1 and type 2 acute myocardial infarction when added to a model that already included cTnI and cTnT concentrations.
Main Results
Marked separation between acute and chronic injury states
The headline finding is striking. The cTnI/cTnT ratio was highest in acute cardiac disease, with a value of 2.06 (95% CI: 1.89-2.26). By comparison, the ratio was 0.66 (95% CI: 0.60-0.72) in chronic cardiac disease and 0.50 (95% CI: 0.43-0.59) in those with no known cardiac disease. In practical terms, the ratio in acute disease was roughly fourfold higher than in individuals without known cardiac disease and about threefold higher than in chronic cardiac disease.
This degree of separation suggests that the ratio is not merely a minor mathematical curiosity. Instead, it appears to encode information about the biological nature of myocardial injury. Low ratios clustered with chronic or non-necrotic states, while higher ratios tracked with acute, more likely necrotic injury.
Consistency across assays and external cohorts
One of the most important questions for any biomarker-based concept is reproducibility. Here, the authors report that the findings were consistent across alternative high-sensitivity cTnI assays and external validation cohorts. That substantially strengthens confidence in the construct. Ratios involving biomarkers measured on different assay platforms can be vulnerable to calibration bias, and the fact that the directional signal persisted argues that the observation is not simply platform noise.
Incremental value in differentiating type 1 from type 2 AMI
The investigators also examined whether incorporating the ratio improves the challenging distinction between type 1 and type 2 acute myocardial infarction. Adding the cTnI/cTnT ratio to a statistical model alongside cTnI and cTnT improved discrimination, with an AUC of 0.73 (95% CI: 0.70-0.76) compared with 0.70 (95% CI: 0.67-0.73) without the ratio; P < 0.01.
This improvement is modest rather than transformative. Still, in a diagnostic space where no single biomarker cleanly resolves the type 1 versus type 2 MI distinction, even incremental gains may be clinically meaningful, especially when integrated with symptoms, electrocardiography, imaging, and dynamic troponin change.
Experimental Mechanistic Findings
The experimental arm is central to the paper’s credibility. In cardiomyocyte models simulating mild nonlethal injury, troponin release was cTnT-dominant, producing a cTnI/cTnT ratio around 0.5. In contrast, lethal injury generated cTnI-dominant release, with a ratio greater than 1.
These observations provide a plausible mechanistic framework for the clinical findings. Chronic or non-necrotic myocardial injury may involve membrane blebbing, increased permeability, intracellular turnover, proteolytic release, or low-grade stress pathways that favor relatively greater measurable cTnT release. By contrast, frank necrosis may liberate larger proportions of structurally bound cTnI, shifting the ratio upward. Although this model is unlikely to capture the full complexity of in vivo troponin biology, it supports the central claim that the ratio reflects biology, not just assay mathematics.
It also aligns with an emerging conceptual distinction in troponin medicine: not all myocardial injury is equivalent. The absolute concentration conveys burden, but the relative composition of released proteins may convey injury phenotype.
Clinical Interpretation
What this means for emergency and inpatient care
For clinicians evaluating elevated troponin, the study suggests that hs-cTnI and hs-cTnT do not simply provide redundant versions of the same information. A higher cTnI/cTnT ratio may point toward acute necrotic injury, whereas a lower ratio may be more consistent with chronic structural disease or non-necrotic myocardial stress.
This has potential relevance in several common scenarios: patients presenting with chest pain but atypical features; critically ill patients with troponin elevation and uncertain ischemic mechanism; those with known chronic heart failure, chronic kidney disease, or stable structural heart disease; and cases where the distinction between type 1 and type 2 MI remains clinically contested.
However, the ratio should not be viewed as a stand-alone diagnostic test. The reported AUC improvement for type 1 versus type 2 MI was statistically significant but modest. Troponin interpretation remains inherently contextual, requiring integration with clinical presentation, serial change, ECG findings, coronary anatomy when available, and alternate causes of injury.
Why the interchangeability assumption may be outdated
Laboratory medicine and clinical cardiology have often accepted a broad equivalence between cTnI and cTnT because both identify myocardial injury and both are guideline-endorsed for MI diagnosis. This study does not invalidate that shared role, but it shows that equivalence for diagnosis does not necessarily mean interchangeability for pathobiological interpretation.
That distinction matters. If cTnI and cTnT reflect overlapping but not identical injury processes, then pairing them may offer additional granularity. The ratio concept therefore turns two familiar biomarkers into a more nuanced composite signal.
Strengths of the Study
The study has several notable strengths. The sample size is large, the diagnoses were centrally adjudicated, and the cohorts were prospective. The authors used a translational design spanning clinical epidemiology, assay validation, and experimental cell models. Reproducibility across alternative hs-cTnI assays and external data sets enhances confidence that the observed pattern is robust. Finally, the study addresses a clinically important question rather than a purely analytical one: whether troponin composition can improve interpretation of elevated values in real-world care.
Limitations and Remaining Questions
Several caveats should temper immediate clinical implementation. First, ratios combining biomarkers from different assay families can be affected by assay architecture, calibration, antibody specificity, lot variation, and pre-analytical factors. Even with cross-assay consistency in this study, local laboratory standardization will be essential before ratio-based thresholds can be generalized.
Second, the abstract does not provide a simple clinically usable cutoff for the ratio, nor does it establish how the ratio should be incorporated into existing accelerated diagnostic pathways. A biologically meaningful signal is not the same as a ready-to-use triage tool.
Third, discrimination between type 1 and type 2 MI improved only modestly. This suggests that the ratio is likely to be most useful as one piece of a multimodal diagnostic framework rather than as a decisive biomarker.
Fourth, external validity across highly diverse populations remains to be clarified, including patients with advanced chronic kidney disease, sepsis, myocarditis, severe heart failure, arrhythmia-related injury, and post-procedural myocardial injury. These are precisely the populations in which chronic or mixed injury patterns are common and where biomarker interpretation is most difficult.
Fifth, experimental models can support plausibility but cannot fully replicate the complexity of in vivo release kinetics, protein degradation, renal clearance, macrophage handling, or tissue-level ischemia-reperfusion biology. The mechanistic explanation is compelling, but still provisional.
Expert Commentary
From a translational standpoint, this study is important because it reframes cardiac troponin from a single-axis marker of quantity to a potentially two-dimensional signal of quantity and injury phenotype. That conceptual move may help explain why patients with similar absolute troponin levels can have very different underlying pathologies.
Current universal definitions of myocardial infarction and guideline-directed acute coronary syndrome pathways emphasize troponin rise and/or fall plus clinical evidence of ischemia. This study does not challenge that framework; rather, it proposes that paired measurement of cTnI and cTnT may sharpen interpretation within it. Before guideline adoption, future work should define standardized ratio reporting, evaluate prospective decision-impact in emergency settings, and test whether ratio-informed care improves resource use, angiography selection, or outcomes.
It would also be valuable to examine whether the ratio changes dynamically over time during acute MI, reperfusion, myocarditis, or decompensated heart failure, and whether trajectory adds more information than a single ratio measurement.
Conclusion
The work by Zimmermann and colleagues is one of the strongest arguments to date that cTnI and cTnT should not always be considered interchangeable. Across a large adjudicated multicohort population and supported by experimental cardiomyocyte models, the cTnI/cTnT ratio was higher in acute cardiac disease and lower in chronic or non-necrotic myocardial injury states. The ratio also modestly improved discrimination between type 1 and type 2 acute myocardial infarction.
For clinicians, the immediate message is not to replace existing diagnostic algorithms, but to recognize that the relationship between cTnI and cTnT may carry clinically meaningful information. For laboratorians and researchers, the study opens a path toward more biologically informed troponin interpretation. If validated prospectively and standardized across platforms, the cTnI/cTnT ratio may become a useful adjunct for distinguishing acute necrotic injury from chronic myocardial injury in difficult diagnostic settings.
Funding and ClinicalTrials.gov
The provided abstract does not specify funding details or a ClinicalTrials.gov registration number. Readers should consult the full Journal of the American College of Cardiology article for complete disclosures, funding sources, and study governance information.
References
1. Zimmermann T, Koechlin L, Walter J, Kimenai DM, Bularga A, Milan G, Sileo A, Fusco D, Mu X, Brunner FJ, Waldeyer C, Sörensen NA, Neumann JT, Muslimovic A, Vukusic K, Nestelberger T, Boeddinghaus J, Lopez-Ayala P, Rumora K, Puelacher C, Gualandro DM, Rentsch K, Strebel I, Diebold M, Twerenbold R, Lindahl B, Denessen EJS, Mingels AMA, Meex S, Mills NL, Marsano A, Hammarsten O, Mueller C, IT-Ratio Consortium. The cTnI/cTnT Ratio in Myocardial Injury: A Multicohort and Experimental Synthesis. Journal of the American College of Cardiology. 2026-02-25;87(17):2211-2230. PMID: 41739020.
2. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD; Executive Group on behalf of the Joint European Society of Cardiology/American College of Cardiology/American Heart Association/World Heart Federation Task Force. Fourth Universal Definition of Myocardial Infarction (2018). Circulation. 2018;138(20):e618-e651. PMID: 30571511.
3. Chapman AR, Bularga A, Mills NL. High-Sensitivity Cardiac Troponin Can Be an Ally in the Fight Against COVID-19. Circulation. 2020;141(22):1733-1735. PMID: 32347780.
4. Sandoval Y, Thygesen K. Myocardial Infarction Type 2 and Myocardial Injury. Clin Chem. 2017;63(1):101-107. PMID: 27803049.
5. Twerenbold R, Costabel JP, Nestelberger T, Campos R, Wussler D, Arbucci R, Cortés M, Boeddinghaus J, Baumgartner B, Nickel CH, Wildi K, du Fay de Lavallaz J, Koechlin L, Potlukova E, Geigy N, Rubini Gimenez M, Badertscher P, Puelacher C, du Fay de Lavallaz J, Miró Ò, Martín-Sánchez FJ, Salgado E, Rentsch K, Osswald S, Mueller C. Outcome of Applying the ESC 0/1-hour Algorithm in Patients With Suspected Myocardial Infarction. J Am Coll Cardiol. 2019;74(4):483-494. PMID: 31319909.
